DarioHealth Corp. (DRIO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 8 | 21 | 28 | 20 | 27 | 22 | 21 | 22 |
| Operating profit | $m | -37 | -69 | ||||||
| Net profit | $m | -29 | -77 | -62 | -59 | -43 | -42 | 68 | -207 |
| EPS reported | $ | -0.81 | 0.69 | ||||||
| Operating cashflow per share | $ | -0.52 | -2.65 | ||||||
| Capex per share | $ | 0.00 | 0.01 | ||||||
| FCF per share | $ | -0.53 | -2.66 | ||||||
| Free cash flow | $m | -26 | -25 | ||||||
| Net debt | $m | 5 | 17 | ||||||
| Book value equity | $m | 68 | 55 | ||||||
| Book value per share | $ | 1.37 | 5.90 | ||||||
| Number of shares | m | 49.63 | 9.34 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 9.72 | ||||||
| P/B LTM | x | 8.32 | 10.25 | ||||||
| P/S LTM | x | 25.26 | 26.90 | ||||||
| P/FCF LTM | x | -21.65 | -22.69 | ||||||
| EV/EBITDA LTM | x | -16.44 | -19.17 | ||||||
| EV/Sales LTM | x | 25.51 | 3.87 | ||||||
| Earnings Yield LTM | % | -7.39% | +10.29% | ||||||
| FCF Yield | % | -4.62% | -4.41% | ||||||
| Quality | |||||||||
| ROE | % | -61.41% | +104.15% | ||||||
| ROIC | % | -36.23% | -78.42% | ||||||
| Operating margin | % | -1.64% | -3.29% | ||||||
| Gross margin | % | +56.64% | +56.09% | ||||||
| FCF/Sales | % | -116.66% | -118.53% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -17.31% | -22.34% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.82 | -0.77 | ||||||
| Net Debt/EBITDA | x | -0.16 | -0.87 | ||||||
| EBIT/Net interest | x | -10.91 | -12.35 | ||||||
| Net debt/market cap | % | +5.52% | +57.04% | ||||||
| Net debt/Equity | x | 0.07 | 0.31 | ||||||
| Gross debt/equity | x | 0.47 | 0.59 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free